Company profile

Ticker
CLDX
Exchange
Website
CEO
Anthony S. Marucci
Employees
Incorporated
Location
Fiscal year end
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
SEC CIK
IRS number
133191702

CLDX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 Aug 20
23 Sep 20
31 Dec 20

News

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
18 Jun 20 Shoos Karen L. NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Penner Harry JR NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Pepin Ronald Incentive Stock Option Common Stock Grant Aquire A No 10.38 14,400 149.47K 14,400
18 Jun 20 Wright Richard M. Incentive Stock Option Common Stock Grant Aquire A No 10.38 42,000 435.96K 42,000
18 Jun 20 Young Diane C. Incentive Stock Option Common Stock Grant Aquire A No 10.38 72,000 747.36K 72,000
70.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 74 43 +72.1%
Opened positions 39 7 +457.1%
Closed positions 8 11 -27.3%
Increased positions 12 10 +20.0%
Reduced positions 9 9
13F shares
Current Prev Q Change
Total value 356.45M 5.95M +5886.7%
Total shares 27.42M 3.55M +672.0%
Total puts 211.7K 13.4K +1479.9%
Total calls 795K 39.3K +1922.9%
Total put/call ratio 0.3 0.3 -21.9%
Largest owners
Shares Value Change
BVF 2.74M $35.62M NEW
RTW Investments 2.61M $33.93M NEW
Redmile 2M $26M NEW
Logos Global Management 2M $26M NEW
Adage Capital Partners GP, L.L.C. 1.75M $22.75M NEW
Ikarian Capital 1.65M $21.42M NEW
Renaissance Technologies 1.64M $21.28M +39.9%
Vivo Capital 1.6M $20.8M NEW
Vanguard 1.3M $16.85M +141.0%
Ra Capital Management 1.15M $14.95M NEW
Largest transactions
Shares Bought/sold Change
BVF 2.74M +2.74M NEW
RTW Investments 2.61M +2.61M NEW
Redmile 2M +2M NEW
Logos Global Management 2M +2M NEW
Adage Capital Partners GP, L.L.C. 1.75M +1.75M NEW
Ikarian Capital 1.65M +1.65M NEW
Vivo Capital 1.6M +1.6M NEW
Ra Capital Management 1.15M +1.15M NEW
Opaleye Management 1.07M +1.07M NEW
Boxer Capital 1M +1M NEW

Financial report summary

?
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Academy, al, allosteric, ameliorating, asymptomatic, Bartlett, breaking, constituted, continuting, convenient, count, CU, DermNet, dermographism, detection, EAACI, enzyme, etiology, exclusively, exploratory, featured, fourth, frequency, Hautarzt, incidence, infusion, intervention, justify, long, magnitude, mediated, mirror, neutrophil, Org, pancreatic, pending, PK, placebo, plasma, prevalence, profound, randomized, resolved, schedule, secreted, serum, spontaneously, subset, synthesized, tryptase, underwriting, underwritten, untreated, Weller, white
Removed: calculation, cavity, clearance, consolidate, cytotoxic, death, enhance, ensuing, epitope, equal, gene, inactivating, investigating, kill, labor, line, longer, MA, mechanism, Needham, notable, NOTCH, occur, occurred, offer, opened, oral, outlined, overcome, pharmacologic, planning, present, proposed, renewed, sensitivity, sequencing, serve, signaling, sizeable, slower, suggest

Patents

GRANT
Utility
Methods of treating by administering anti-kit antibodies
22 Sep 20
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies.
GRANT
Utility
Treatment of eosinophil or mast cell related disorders
15 Sep 20
Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).
GRANT
Utility
Anti-ErbB antibodies and methods of use thereof
18 Aug 20
Provided herein are compositions, methods and uses involving antibodies that bind to ErbB, a receptor tyrosine kinase, and modulate the activity of ErbB.
GRANT
Utility
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
2 Jun 20
This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody.
APP
Utility
Anti-ALK Antibodies and Methods for Use Thereof
21 May 20
Provided herein are compositions, methods and uses involving antibodies that specifically bind to ALK, a receptor tyrosine kinase, and modulate the expression and/or activity of ALK.